Lenvakast 4mg What is Lenvatinib?
Lenvakast mecidine contains the active ingredient Lenvatinib, which is indicated for the treatment of patients with liver and kidney cancer. Lenvatinib is FDA approved under the brand name Lenvima for the treatment of cancer.
Information Lenvakast 4mg Lenvatinib treats liver and kidney cancer
- Drug name: Lenvakast .
- Ingredients: Lenvatinib .
- Content: 4mg.
- Dosage form: Capsules.
- Specification: Box of 3 blisters, blister of 10 tablets.
- Manufacturer: Aprazer Healthcare
- Origin: India.
Mechanism of action of active ingredient Lenvatinib
Active ingredient lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that selectively inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR) and VEGFR3 (FLT4).
In addition to other oncogenic and oncogenic pathways- relevant RTKs include FGFR1, 2, 3, and 4 receptors, fibroblast growth factor (FGF) receptors include PDGFRα, KIT and Platelet-derived RET (PDGF).
In addition, lenvatinib has direct, selective anti-proliferative activity in activated FGFR signaling-dependent liver cell lines, which is attributed to lenvatinib inhibition of FGFR signaling.
Indications for treatment with the drug Lenvakast
- Thyroid cancer : single agent for patients with recurrent or metastatic, advanced radioiodine-resistant DTC.
- Renal cell carcinoma : in combination with everolimus , for patients with advanced RCC following a prior antiangiogenic therapy.
- Liver cancer : as first-line therapy in patients with unresectable HCC.
Contraindications to treatment with the drug Lenvakast
- Hypersensitivity to the active substance Lenvatinib or to any of the excipients of the drug Lenvakast.
- Breastfeeding women.
Dosage of Lenvakast 4mg
For thyroid cancer: The recommended dose is 24 mg once daily.
If the condition is severe such as the patient has liver or kidney problems, the recommended dose is changed to 14 mg/day.
How to use Lenvakast
- Your doctor may reduce your dose if you experience major side effects.
- Capsules can be taken with or without food.
- Swallow the capsule whole with water or in the dissolved form. Leave for at least 10 minutes then stir for at least 3 minutes until the capsule is completely dissolved.
- Take the capsule at the same time every day,
- Do not open the capsule as interaction with the powder could be harmful.
What to do in case of an overdose of Lenvakast ?
- Call 911 immediately or go to the nearest local health station.
- Of course, you’ll need to keep a record and bring a list of all the medications you’ve taken, including prescription and over-the-counter drugs.
What should I do if I miss a dose?
- If you forget to take a dose, take it as soon as possible.
- But if it is almost time for your next dose, skip the missed dose and take your next dose at the scheduled time.
- Do not take twice the prescribed dose.
Precautions when using Lenvakast
Tell your doctor if you have ever:
- Heart disease, high blood pressure; heart attack, heart failure , stroke, or blood clot;
- headache or vision problems;
- Bleeding problems; perforation (a hole or tear) in your stomach or intestines;
- Seizure disorder; kidney or liver disease.
Effects on pregnant and lactating women
Pregnant women: v ì drugs Lenvakast can be absorbed through the skin and lungs and can cause harm to the fetus, women who are pregnant or may be pregnant should not use this medication or breathe the dust from capsule .
Breastfeeding women: d o probable risk for infants, breast-feeding is not recommended while using drugs Lenvakast and at least 1 week after stopping treatment. Consult your doctor before breast-feeding.
Lenvakast side effects
Common side effects may include:
- Stomach pain, nausea, vomiting, diarrhea;
- Anorexia, weight loss;
- Abnormal thyroid function tests;
- Muscle or joint pain;
- Swelling in your hands and feet;
- Mouth Sores;
- Red, itchy, or peeling skin on the hands or feet;
- Headache, fatigue;
- Cough, difficulty breathing, hoarseness;
Drug interactions with Lenvakast 4mg Lenvatinib
Effects of other medicinal products on lenvatinib.
Drug therapy: Co-administration of lenvatinib, carboplatin and paclitaxel had no significant effect on the pharmacokinetics of any of these 3 agents.
Effects of lenvatinib on other medicinal products: Drugs (DDI) in cancer patients showed that plasma concentrations of midazolam (a sensitive CYP3A and Pgp substrate) were not altered in the presence of lenvatinib. Therefore, no significant Lenvakast drug interactions are expected between lenvatinib and other CYP3A4/Pgp substrates.
Oral contraceptives: It is currently unclear whether lenvatinib can reduce the effectiveness of hormonal contraceptives, and therefore women using oral hormonal contraceptives should add an additional method. barriers.
How much does Lenvakast 4mg cost?
To know how much is the drug Lenvakast? Please COMMENT below or Contact 0933049874 (Zalo/ Facebook/ Viber/ Whatsapp) to buy and sell brand-name drugs in Ho Chi Minh City, Hanoi, Da Nang City, Can Tho City,… nationwide.
How to store medicine?
- You should store Lenvakast at room temperature, in a cool, dry place, away from direct sunlight.
- You should not store the medicine in the refrigerator.
- Keep the medicine out of the reach of children.
- Do not throw medicine down the toilet or plumbing.
The above article is for reference only and is not a substitute for medical diagnosis or treatment. Readers should only follow the instructions of the doctor who is treating you, Index-China disclaims responsibility if problems occur.
Reputable source ThuocLP Vietnamese: Lenvakast medicine 4mg Lenvatinib treatment of liver and kidney cancer
Assoc.Prof.Dr. Tran Ngoc Anh is currently Hanoi Medical University Hospital, Associate Professor, Department of Internal Medicine, Gastroenterology and Head of Department of General-Uematology of Hanoi Medical University. Consulting doctor at ThuocLP Pharmacy.
Professional qualifications, Academic degrees – Education:
Graduated from General Practitioner System, Hanoi Medical University
Graduated with a Master degree in Internal Medicine, Hanoi Medical University
Graduated from the training program specialized in Gastrointestinal, Henri Mondor Institute Center, University of Paris 6, French Republic 1996-1997; 1999
Graduated from the training program specialized in Gastrointestinal, North Royal Sydney Hospital, Australia; 2002
Graduated from a training program specialized in chronic liver diseases, Pizza, Italy 2009
Graduated with a PhD in Gastrointestinal, Hanoi Medical University
Associate Professor, Gastroenterology, Hanoi Medical University
Training and Scientific Research:
Published more than 200 articles in domestic and international specialized journals
Editor of many monographs and participates in compiling 2 textbooks.
Guide many students and graduate students of Hanoi Medical University
Manager of many grassroots research projects
Certificate of Good Clinical Practice (GCP: 2012, 2015), Ministry of Health
Specialized certificates: General gastrointestinal endoscopy, Interventional gastrointestinal endoscopy, General gastrointestinal ultrasound, Interventional gastrointestinal ultrasound (Bach Mai BV), Chronic liver disease.